We are live on ! Find out more
CBAY

Cymabay Therapeutics

Delisted

CBAY was delisted on the 21st of March, 2024.

145 hedge funds and large institutions have $322M invested in Cymabay Therapeutics in 2020 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 41 increasing their positions, 36 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 21

21% more funds holding

Funds holding: 120145 (+25)

14% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 36

23% less capital invested

Capital invested by funds: $416M → $322M (-$94.1M)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

52% less call options, than puts

Call options by funds: $1.9M | Put options by funds: $3.98M

Holders
145
Holders Change
+25
Holders Change %
+20.83%
% of All Funds
2.57%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
46
Increased
41
Reduced
36
Closed
21
Calls
$1.9M
Puts
$3.98M
Net Calls
-$2.08M
Net Calls Change
-$4.62M
Name Holding Trade Value Shares
Change
Change in
Stake
ACA
1
Avoro Capital Advisors
New York
$59.1M
BlackRock
2
BlackRock
New York
$30.9M +$1.93M +255,336 +5%
BC
3
Boxer Capital
California
$23M
Vanguard Group
4
Vanguard Group
Pennsylvania
$19.7M +$408K +53,892 +2%
BBA
5
Baker Bros. Advisors
New York
$16.6M -$2.72M -359,266 -11%
Citadel Advisors
6
Citadel Advisors
Florida
$14.5M +$2.29M +301,870 +14%
State Street
7
State Street
Massachusetts
$10.4M +$1.27M +167,833 +10%
FCMI
8
Foresite Capital Management IV
California
$10.3M
FCMI
9
Foresite Capital Management III
California
$9.42M
CC
10
Commodore Capital
New York
$8.53M +$11.2M +1,486,107 New
Adage Capital Partners
11
Adage Capital Partners
Massachusetts
$8.32M
Millennium Management
12
Millennium Management
New York
$7.73M -$2.55M -336,355 -20%
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$7.24M -$3.21M -423,737 -25%
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
$7.19M +$1.57M +207,251 +20%
Two Sigma Advisers
15
Two Sigma Advisers
New York
$6.98M +$6.11M +807,300 +198%
Two Sigma Investments
16
Two Sigma Investments
New York
$6.4M +$6.59M +870,584 +355%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$5.97M +$173K +22,815 +2%
Goldman Sachs
18
Goldman Sachs
New York
$5.4M +$6.44M +850,404 +939%
Northern Trust
19
Northern Trust
Illinois
$4.19M -$102K -13,450 -2%
SCM
20
Sio Capital Management
New York
$3.37M -$4.33M -571,897 -49%
VC
21
Vivo Capital
California
$3.36M -$11.4M -1,503,962 -72%
PPA
22
Parametric Portfolio Associates
Washington
$3.12M -$54.8K -7,233 -1%
VVM
23
Versant Venture Management
California
$3.12M
Charles Schwab
24
Charles Schwab
California
$2.98M -$5.49K -725 -0.1%
KPWS
25
Kestra Private Wealth Services
Texas
$2.36M +$765K +101,000 +34%

CBAY Hedge Fund Activity: Q4 2020 in Review

145 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q4 2020, worth a combined $322M — down 23% from $416M a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new CBAY positions and 21 closed out — a net gain of 25 holders — while 41 added to existing stakes and 36 trimmed.

The largest buyer was Two Sigma Investments, adding an estimated $6.59M. The largest seller was Invesco, cutting an estimated $12.6M.

  • 145 institutional investors held Cymabay Therapeutics (CBAY) as of Q4 2020, up from 120 in Q3 2020.
  • Funds reported $322M of Cymabay Therapeutics stock for Q4 2020, down 23% quarter-over-quarter.
  • 46 funds opened new Cymabay Therapeutics positions in Q4 2020 and 21 closed out, a net change of +25 holders.
  • The largest Cymabay Therapeutics buyer in Q4 2020 was Two Sigma Investments, an estimated $6.59M added.
  • The largest Cymabay Therapeutics seller in Q4 2020 was Invesco, an estimated $12.6M sold.

Based on aggregated 13F filings for Q4 2020.